« Back
Home /
Medroxyprogesterone

Medroxyprogesterone

Item no.	HY-B0648-500mg
Manufacturer	MedChem Express
CASRN	520-85-4
Amount	500 mg
Quantity options	100 mg 10 mM/1 mL 1 g 500 mg
Category	Oncology Food Safety Hormones Inhibitors & Compound Libraries Small Molecules By Organ Breast Cancer
Type	Inhibitors
Specific against	other
Purity	98.82
Citations	[1]Saitoh M, et al. Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-kappaB cascade in human breast cancer cells. Endocrinology. 2005 Nov;146(11):4917-25.\|[2]Ito F, et al. Medroxyprogesterone acetate enhances monocyte-endothelial interaction under flow conditions by stimulating the expression of cell adhesion molecules. J Clin Endocrinol Metab. 2014 Jun;99(6):2188-97.\|[3] Freudenberger T, et al. Differential effects of medroxyprogesterone acetate on thrombosis and atherosclerosis in mice. Br J Pharmacol. 2009 Dec;158(8):1951-60.\|[4]Yusop SNW, et al. Medroxyprogesterone derivatives from microbial transformation as anti-proliferative agents and acetylcholineterase inhibitors (combined in vitro and in silico approaches). Steroids. 2020 Dec;164:108735.
Smiles	C[C@@]1([C@@]2(O)C(C)=O)[C@](CC2)([H])[C@@](C[C@H](C)C3=CC4=O)([H])[C@]([C@]3(CC4)C)([H])CC1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	17α-Hydroxy-6α-methylprogesterone,U8840
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Neuroscience-Neuromodulation
Manufacturer - Targets	Progesterone Receptor
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	344.50
Product Description	Medroxyprogesterone (17α-Hydroxy-6α-methylprogesterone) is a synthetic human variant of progesterone that is a progesterone receptor agonist with oral activity. Medroxyprogesterone can induce cell proliferation through the PI3K/Akt signaling pathway. Medroxyprogesterone has an inhibitory effect on atherosclerosis in mice. The progesterone agonist activity of Medroxyprogesterone is less effective than Medroxyprogesterone acetate (HY-B0469)[1][2][3][4].
Manufacturer - Research Area	Endocrinology; Cancer
Solubility	DMSO: 50 mg/mL (ultrasonic)
Manufacturer - Pathway	Vitamin D Related/Nuclear Receptor
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-B0648-500mg-safety-datasheet.pdf